TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22463922

Group type: EXPERIMENTAL
Intervention: SAR236553 50 mg Q2W
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: SAR236553 100 mg Q2W
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: SAR236553 150 mg Q2W
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: SAR236553 200 mg Q4W
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: SAR236553 300 mg Q4W
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: SAR236553
Number of subjects: 183
Study: 20934557

Group type: EXPERIMENTAL
Intervention: 200-mg intravenous bolus of potassium canrenoate followed by a daily 25-mg dose of spironolactone for 6 months
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 1600
Study: 18074183

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Surgical controls
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 31
Study: 15725087

Group type: EXPERIMENTAL
Intervention: Pre-emptive immunotherapy
Number of subjects: 65
Study: 12783152

Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10839223

Group type: EXPERIMENTAL
Intervention: Wet Suits (WS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No Wet Suits (Control)
Number of subjects: 19
Study: 9119352

Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Chlormezanone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 2062631

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 6501905

Group type: EXPERIMENTAL
Intervention: Purified trivalent sub‐unit influenza vaccine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 14‐valent pneumococcal vaccine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 69
Study: 30281866

Group type: EXPERIMENTAL
Intervention: HDM sublingual tablets (300 index of reactivity) once daily for 52 weeks
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 30143003

Group type: EXPERIMENTAL
Intervention: Clinical medication review (CMR) focused on patients' preferences, personal goals, and health-related complaints.
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Secondary outcomes include healthcare utilisation, number and type of drug changes, number and type of health-related goals, scores on goal attainment scale (GAS), and number and type of drug-related problems (DRPs) and interventions.
Number of subjects: 630
Study: 26414074

Group type: EXPERIMENTAL
Intervention: Injection speed of 0.3 ml/s (15 seconds)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Injection speed of 0.15 ml/s (30 seconds)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Injection speed of 0.1 ml/s (45 seconds)
Number of subjects: 36
Study: 24899160

Group type: EXPERIMENTAL
Intervention: 6 mg/d lutein (low-dose)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 12 mg/d lutein (high-dose)
Number of subjects: 89

Group type: COMPARATOR
Intervention: 0 mg/d lutein (placebo)
Number of subjects: 89
Study: 22992291

Group type: EXPERIMENTAL
Intervention: Active group (74 patients) that viewed former self-reported PROMs scores and discussed the joint fitness programme.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (73 patients) that continued treatment based on recorded PROMs and clinical assessment.
Number of subjects: 147
Study: 20405788

Group type: EXPERIMENTAL
Intervention: Chewing gum A
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chewing gum B
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cotton ball
Number of subjects: 10

Group type: COMPARATOR
Intervention: Parafilm M
Number of subjects: 10
Study: 18254326

Group type: EXPERIMENTAL
Intervention: Nebulized Pulmicort respimat
Number of subjects: 44

Group type: COMPARATOR
Intervention: Budesonide aqueous nasal spray
Number of subjects: 44
Study: 17547948

Group type: EXPERIMENTAL
Intervention: Lingualized posterior occlusal forms
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anatomic posterior occlusal forms
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0-degree posterior occlusal forms
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lingualized vs Anatomic posterior occlusal forms
Number of subjects: 45
Study: 15452011

Group type: EXPERIMENTAL
Intervention: Private sector strategies (training, regulation, incentives)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Training private providers
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination of strategies
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Robust designs (randomized controlled trials)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Short-term effects
Number of subjects: 71
Study: 10624997

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9186385

Group type: COMPARATOR
Intervention: DTP-IPV vaccine alone (n = 43)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DTP-IPV vaccine with PVRV (n = 41)
Number of subjects: 84
Study: 8233146

Group type: EXPERIMENTAL
Intervention: Oral laxatives
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conditional rectal cathartics
Number of subjects: 136
Study: 3887636

Group type: EXPERIMENTAL
Intervention: DHE‐Heparin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Impedance plethysmography (IPG)
Number of subjects: 105
Study: 31557061

Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (EAG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture group (AG)
Number of subjects: 0
Study: 29549968

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (n=11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition (n=8)
Number of subjects: 19
Study: 28257727

Group type: EXPERIMENTAL
Intervention: 0.75-mm retainer
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1.00-mm retainer
Number of subjects: 80
Study: 25158943

Group type: EXPERIMENTAL
Intervention: ILM peeling group (30 eyes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ILM not peeling group (30 eyes)
Number of subjects: 60
Study: 25608550

Group type: EXPERIMENTAL
Intervention: Spirituality Promotion Program (SPP) for young nurses, completed over 8 weeks.
Number of subjects: 41
Study: 21511473

Group type: EXPERIMENTAL
Intervention: Bright light exposure for two hours for four days after extubation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no bright light exposure).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bright light exposure.
Number of subjects: 0
Study: 19825060

Group type: EXPERIMENTAL
Intervention: Jaw-Thrust-Device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Esmarch manoeuvre
Number of subjects: 50

Group type: COMPARATOR
Intervention: nasopharyngeal airway
Number of subjects: 50

Group type: COMPARATOR
Intervention: oropharyngeal airway
Number of subjects: 50
Study: 17785483

Group type: EXPERIMENTAL
Intervention: Nitrofurazone-impregnated urinary catheters
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard silicone catheters
Number of subjects: 212
Study: 15293865

Group type: EXPERIMENTAL
Intervention: AS 195 360mg once daily for 6 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 11253467

Group type: EXPERIMENTAL
Intervention: Cardiac pacing
Number of subjects: 56000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56000
Study: 9683395

Group type: EXPERIMENTAL
Intervention: L-tryptophan (30 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (caffeine free diet Coca-Cola)
Number of subjects: 6
Study: 7832179

Group type: EXPERIMENTAL
Intervention: Cocaine use during methadone maintenance (35 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cocaine use during buprenorphine maintenance (2 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cocaine use during buprenorphine maintenance (6 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cocaine use during methadone maintenance (120 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Methadone maintenance (35 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Buprenorphine maintenance (2 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Buprenorphine maintenance (6 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Methadone maintenance (120 mg)
Number of subjects: 125
Study: 2979249

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS) containing bicarbonate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) without bicarbonate (chloride ions instead)
Number of subjects: 40
Study: 30637672

Group type: EXPERIMENTAL
Intervention: Intervention group (alcohol prevention program)
Number of subjects: 12738

Group type: COMPARATOR
Intervention: Control group (education as normal)
Number of subjects: 12738

Group type: EXPERIMENTAL
Intervention: Both groups (adjusted for recanting)
Number of subjects: 12738

Group type: EXPERIMENTAL
Intervention: Both groups (males vs females)
Number of subjects: 12738
Study: 28004395

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CMD
Number of subjects: 43
Study: 24962607

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24 International Units, twice-daily for 6 weeks) combined with social cognition training (2 × 1 hour weekly sessions for 6 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo nasal spray combined with social cognition training (2 × 1 hour weekly sessions for 6 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24 International Units, twice-daily for 6 weeks)
Number of subjects: 52
Study: 23486191

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 113
Study: 21857390

Group type: EXPERIMENTAL
Intervention: Iron supplementation (0, 1, or 2 mg iron/kg/d) from 6 weeks to 6 months of age
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg group)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) infants
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 285
Study: 18827732

Group type: EXPERIMENTAL
Intervention: 700 microg dexamethasone drug delivery system via a 22-gauge applicator insertion (n = 20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 700 microg dexamethasone drug delivery system via a pars plana incisional placement (n = 10)
Number of subjects: 30
Study: 16679203

Group type: EXPERIMENTAL
Intervention: Acrylic splint rapid maxillary expander followed by fixed appliances
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 51
Study: 15570141

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 19
Study: 12880497

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 11120722

Group type: EXPERIMENTAL
Intervention: Oestrogen alone, oral or transdermal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogen with cyclical progestagen (norethisterone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral route
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implant (oestrogen and testosterone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9124831

Group type: EXPERIMENTAL
Intervention: Once-weekly azithromycin (10 mg/kg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Once-weekly azithromycin (5 mg/kg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Once-daily amoxicillin (20 mg/kg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both azithromycin and amoxicillin groups
Number of subjects: 159
Study: 1433775

Group type: EXPERIMENTAL
Intervention: 20 g/day arginine hydrochloride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mixed amino acid solution (Travasol)
Number of subjects: 30
Study: 4033356

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31072222

Group type: EXPERIMENTAL
Intervention: Reaching Performance Scale for Stroke (RPSS–Close and Far targets)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Trunk compensatory movements
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Overall regression models
Number of subjects: 141
Study: 30335708

Group type: EXPERIMENTAL
Intervention: Two levels of immersive virtual reality simulation (VRS)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study: 27270597

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 105
Study: 24891007

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22883586

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional tonsillectomy
Number of subjects: 70
Study: 20610202

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (4%) scrub followed by alcohol impregnated with iodine (1%) solution
Number of subjects: 120
Study: 18343087

Group type: EXPERIMENTAL
Intervention: Test of Memory Malingering (TOMM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dot Counting Test
Number of subjects: 108

Group type: COMPARATOR
Intervention: Analog students (control group)
Number of subjects: 108
Study: 16166438

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Central laboratory immunohistochemistry (10H8‐IHC)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Outside/local laboratory immunohistochemistry
Number of subjects: 2600

Group type: COMPARATOR
Intervention: BCIRG central laboratory 10H8‐IHC
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Unspecified FISH assay methods at outside/local laboratories
Number of subjects: 2600
Study: 12924672

Group type: EXPERIMENTAL
Intervention: Short-term individual psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance rated from patient perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance rated from therapist perspective
Number of subjects: 0
Study: 10515836

Group type: EXPERIMENTAL
Intervention: 5 microgram of gB antigen with MF59 at 0, 1, and 2 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 30 microgram of gB antigen with MF59 at 0, 1, and 2 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 5 microgram of gB antigen with MF59 at 0, 1, and 4 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 30 microgram of gB antigen with MF59 at 0, 1, and 4 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 5 microgram of gB antigen with MF59 at 0, 1, and 6 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 30 microgram of gB antigen with MF59 at 0, 1, and 6 months
Number of subjects: 95
Study: 8822431

Group type: EXPERIMENTAL
Intervention: Ovulation induction with intrauterine insemination (IUI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ovulation induction with timed intercourse (TI)
Number of subjects: 100
Study: 1793648

Group type: EXPERIMENTAL
Intervention: Advice to blow noses
Number of subjects: 84

Group type: COMPARATOR
Intervention: No advice given
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Naturally good nose blowers
Number of subjects: 84

Group type: COMPARATOR
Intervention: Not naturally good nose blowers
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Surgical intervention (ventilating tubes)
Number of subjects: 84
Study: 6167831

Group type: EXPERIMENTAL
Intervention: Cisplatinum/Bleomycin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methotrexate/vindesine
Number of subjects: 21
Study: 31345051

Group type: EXPERIMENTAL
Intervention: Interdisciplinary Home‐bAsed Reablement Program (I‐HARP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 31115032

Group type: EXPERIMENTAL
Intervention: Simendan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 28202051

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (476 exams in 12 centers)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (310 exams in 9 centers)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (85 exams in 3 centers)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (199 exams in 9 centers)
Number of subjects: 476
Study: 26048134

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) after a standard meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) after a high‐fat meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) in the fed state (standard meal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg (8 × 50 mg capsules) in the fed state (high‐fat meal)
Number of subjects: 32
Study: 23528399

Group type: EXPERIMENTAL
Intervention: Balneopeloid therapy with irrigation of high mineralized natural water and application of sapropel mud
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional periodontal treatment
Number of subjects: 127
Study: 21716273

Group type: EXPERIMENTAL
Intervention: Verapamil (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine (various doses)
Number of subjects: 0
Study: 19699916

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 130
Study: 16752267

Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus plantarum LB931
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 191
Study: 15596605

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/d for 6 weeks, then 10 mg/d
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 11684621

Group type: EXPERIMENTAL
Intervention: Low-copay group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-copay group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-copay group
Number of subjects: 0
Study: 9729054

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (topical corticosteroid)
Number of subjects: 10
Study: 7982651

Group type: EXPERIMENTAL
Intervention: Propranolol plus isosorbide‐5‐mononitrate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Elective sclerotherapy
Number of subjects: 30
Study: 2500248

Group type: EXPERIMENTAL
Intervention: 20-cm2 nitroglycerin adhesive transdermal patch applied for a single 24-hour period (q24hr)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2% nitroglycerin ointment applied over a 50-cm2 area every eight hours (q8hr)
Number of subjects: 24
Study: 4400557

Group type: EXPERIMENTAL
Intervention: Pericyazine
Number of subjects: 15
Study: 528095

Group type: EXPERIMENTAL
Intervention: Phenobarbital tablets, USP, 100 mg (7 different brands)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Phenobarbital tablets, USP, 100 mg (Preparations A and E)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Phenobarbital tablets, USP, 100 mg
Number of subjects: 5
Study: 31880365

Group type: COMPARATOR
Intervention: Amisulpride
Number of subjects: 45

Group type: COMPARATOR
Intervention: l-DOPA
Number of subjects: 45
Study: 31790404

Group type: EXPERIMENTAL
Intervention: Permagarden intervention
Number of subjects: 884
Study: 29606364

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 4710

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 4710

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 4710

Group type: COMPARATOR
Intervention: Artesunate-amodiaquine
Number of subjects: 4710
Study: 26272736

Group type: EXPERIMENTAL
Intervention: Single Test-Stimulus (STS) protocol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bath-Thermode protocol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Two-Thermodes protocol
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Hand immersion conditioning pain
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Thermode pain
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conditioned test-stimulus pain scores for Bath-Thermode
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Conditioned test-stimulus pain scores for STS
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conditioned test-stimulus pain scores for Two-Thermodes
Number of subjects: 65
Study: 23994951

Group type: EXPERIMENTAL
Intervention: Metronidazole 750 mg ± miconazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg ± miconazole
Number of subjects: 43
Study: 22863663

Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard of care rehabilitation
Number of subjects: 26
Study: 19246922

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no drugs for 14 days)
Number of subjects: 20
Study: 17209663

Group type: EXPERIMENTAL
Intervention: Serotonergic drugs (SSRIs, dexfenfluramine, 5‐HT2C receptor agonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine, dexfenfluramine, fluoxetine, chlorophenylpiperazine (mCPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐hydroxytryptophan, mCPP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐HT2C receptor selective agonists (lorcaserin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐HT6 receptor antagonists (PRX‐07034, BVT74316)
Number of subjects: 0
Study: 15189585

Group type: EXPERIMENTAL
Intervention: Trauma disclosure intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (writing about plans for the next day)
Number of subjects: 50
Study: 10715302

Group type: EXPERIMENTAL
Intervention: ACVBP
Number of subjects: 673

Group type: COMPARATOR
Intervention: m-BACOD
Number of subjects: 673